How Accurate Are ThyroSeq & Afirma in Indeterminate Nodules?

Receiving an “indeterminate” biopsy result can be incredibly stressful and confusing. It is natural to want a straight answer, but molecular tests like ThyroSeq and Afirma do not provide an absolute “yes” or “no” diagnosis. Instead, they analyze the genetic material in your biopsy to calculate the probability that a nodule is cancerous. While these tests are highly accurate at ruling out cancer, they are less definitive when ruling it in.

Why Is My Biopsy “Indeterminate”?

To understand molecular testing, it helps to know why your fine needle aspiration (FNA) biopsy didn’t give a definitive answer. An indeterminate result—often categorized as Bethesda III (atypia of undetermined significance) or Bethesda IV (suspicious for a follicular neoplasm)—means the cells look abnormal under a microscope ^[1][2].

However, pathologists often cannot tell the difference between a benign growth (an adenoma) and a cancer (a carcinoma) just by looking at a few cells from a needle. Diagnosing certain thyroid cancers requires seeing whether the tumor has invaded its surrounding capsule or blood vessels, which can only be definitively proven by examining the entire surgically removed nodule ^[1]. Molecular testing was developed to help clarify this gray area and guide decision-making before surgery.

Rule-Out vs. Rule-In Performance

When your medical team reviews a molecular test, they look at two statistical measures to guide your care:

• Rule-Out Power (Negative Predictive Value): This is the test’s greatest strength. If your ThyroSeq or Afirma result is negative (or benign), the chance that the nodule is actually cancerous drops significantly. In major validation studies, a negative result left roughly a 1% to 4% residual risk of cancer ^[3][1][2]. Because this low risk is similar to a completely benign biopsy, a negative result often allows patients to safely choose active surveillance (a planned schedule of regular ultrasound monitoring) instead of diagnostic surgery ^[3][1].
• Rule-In Power (Positive Predictive Value): These tests are less perfect at confirming cancer. A positive or “suspicious” result means the nodule has genetic alterations associated with cancer, which may prompt a recommendation for diagnostic surgery. However, the likelihood that a positive nodule is truly cancerous in validation cohorts generally ranges from 47% to 66% ^[3][4][5]. This means a significant number of positive or suspicious nodules will still turn out to be benign once they are surgically removed and examined ^[5].

Your Individual “Pretest” Risk

It is critical to understand that the performance figures above are estimates from large study populations. Your personal risk depends on your pretest probability—how likely cancer was before the test was even run. Your doctor combines the molecular result with several other factors:

• Ultrasound Findings: If an ultrasound shows highly suspicious features, the nodule is already high-risk. A negative molecular test might not be reassuring enough to override a highly suspicious ultrasound ^[6]. Conversely, molecular testing is highly effective at shifting the treatment plan for low- or intermediate-suspicion nodules ^[6].
• Other Clinical Factors: Your risk is also influenced by your specific Bethesda category (III vs. IV), the size and growth rate of the nodule, your family history, and whether you have multiple suspicious nodules in your goiter ^[1][2].
• Local Cancer Rates: The accuracy of the test also depends on how common thyroid cancer is in the clinic or region where you are treated. In areas with higher baseline thyroid cancer rates, a positive test is more likely to be a true positive, but a negative test is also slightly less reassuring ^[3][1][7].

Comparing ThyroSeq and Afirma

Patients often wonder if they should push for ThyroSeq v3 or the Afirma Genomic Sequencing Classifier (GSC). While they analyze different molecular signals, they perform very similarly overall. A randomized clinical trial comparing the two found that differences in specificity and positive predictive value were not statistically significant ^[5]. Other large reviews have found no clear superiority of one over the other ^[8][9]. Neither test is universally better; your doctor’s recommendation will likely depend on their clinic’s experience and which test is validated for your specific situation.

Important Limitations to Consider

While molecular testing has revolutionized thyroid care, it is not a perfect system. You and your doctor should consider a few limitations:

• False Negatives and Residual Risk: While rare, a test can occasionally miss a cancer. In validation studies, the false-negative rate (the percentage of actual cancers missed by the test) was around 0.6% to 3% ^[10][4]. Because a small residual risk remains, a negative result requires a structured schedule of follow-up ultrasounds to ensure the nodule isn’t growing ^[1].
• “Gray Area” Mutations: Some genetic alterations (such as RAS mutations) can be found in malignant tumors, but also in benign growths and borderline lesions ^[11]. A test might flag these mutations, leading to surgery for a lesion that ultimately behaves in a benign or low-risk manner ^[12].
• Inadequate Samples: Sometimes, the biopsy sample sent to the lab simply does not contain enough genetic material to run the test ^[4][13]. If this happens, you may need a repeat biopsy or diagnostic surgery.
• Surgical Scope for Multinodular Goiter: A positive result raises your risk profile, but it does not automatically dictate the extent of your surgery. For a single indeterminate nodule, removing just the half of the thyroid containing the nodule (a lobectomy) may be sufficient in many cases ^[11]. However, because you have a multinodular goiter, factors like the presence of multiple nodules on both sides, nodule size, or compressive symptoms may mean a total thyroidectomy (removing the entire gland) is more appropriate.
• Cost and Insurance: These advanced tests are expensive. While models suggest they save the healthcare system money by averting unnecessary surgeries ^[14][15], your personal out-of-pocket cost depends entirely on your insurance coverage, deductibles, and whether the lab is in-network.

Molecular testing is an invaluable tool, but it is just one piece of the puzzle. The most appropriate care plan comes from combining these genetic insights with your imaging, clinical history, and personal values.